AASLD, Liver Meeting in Boston, Nov. 2012

[Advocate1955]

Hi all,

I've seen some posts on the forum over the weekend about the interesting results of recent trials for various new drugs being researched for HCV treatment coming out of the AASLD conference in Boston.

I have posted some of the press releases in my journals, in case anyone is interested in reading them there.  You can also find them as press releases on each of the drug companies' websites.  Here is the link to my journals:  
http://www.medhelp.org/user_journals/list/1739543?personal_page_id=2242526

Here is a summary of some of the announcements so far:
Janssen presented information about its protease inhibitor simeprever (TMC435) at the AASLD conference in Boston.   79% of treatment naive attained SVR, 48% of treatment experienced attained SVR, and 62 of treatment experienced with F4 attained SVR.

Vertex presented information at the AASLD conference in Boston.   Vertex's VX-135, an oral nucleotide, demonstrated a median 4.54 log 10 reduction in HCV RNA after dosing once daily for seven days in treatment naive patients both w/ and w/o Ribavirin.  Vertex will be conducting Phase 2 trials of VX-135 combined with simeprevir (TMC435).

100% of treatment naive Hep C, G1 patients achieved SVR4 with Gilead's Sofosbuvir (GS-7977), combined with GS-5885 and Ribavirin, according to Gilead’s announcement at the AASLD conference in Boston.

Merck announced that 96% of trial patients achieved SVR12 with its protease inhibitor (MK-5172) combined with Interferon and Ribavirin.  Merck plans to begin other Phase 2 studies soon.

Boehringer Ingelheim announced at the AASLD conference in Boston that faldaprevir (BI201335) and BI207127 combined with Ribavirin showed up to 85% SVR in treatment naive Hep C patients and up to 69% SVR in G1a and 1b patients, including some with advanced liver disease.  According to Boehringer Ingelheim, subtype, genome type, and gender proved to be significant predictors for success.  Boehringer Ingelheim will also begin Phase 3 trials that will include Cirrhotics soon. Faldaprevir (BI201335) is a direct acting antiviral small molecule protease inhibitor.

Abbott announced at the AASLD meeting in Boston that its triple DAA regimen which produced high rates of SVR both in treatment naive and null responders both with and without Ribavirin, although results with Ribavirin are higher.  According to Abbott’s press release, the SVR rates after 12 weeks of treatment were:
GT1, treatment naive 97.5% SVR, null responders 93.3% SVR
GT1a, treatment naive 96% SVR, null responders 89% SVR
GT1b, treatment naive 100% SVR, null responders 100% SVR
ABT-450r is a protease inhibitor, ABT-333 is a polymerase inhibitor, and ABT-267 is a NS5A inhibitor.  Phase 3 will be enrolling.

Bristol-Myers Squibb Company announced at the AASLD meeting in Boston that the dual regimen of the NS3 protease inhibitor asunaprevir (ASB) with the NS5A inhibitor daclatasvir (DCV)  without Interferon or Ribavirin showed up to 78% SVR12 rates in G1b's who were previously null responders.

Advocate1955

[yodennis]

Thanks for posting your generous journals! d

[jules2551]

Thanks for the posts Advocate.  I have been reading all of your journals.  This looks very promising!

Jules

[orphanedhawk]

Thanks for posting.
The future of hep C treatment is exciting and the race is on !